RE:RE: The Pathfossi, "My God, do you really believe what you're writing?
PROPH.. CZO's major client undergoing reoganization
J&J has transferred the cosmetic care to Kenvue.
Why should our business suffer as a result?
If only for a short time and not over several quarters"
It appears that fossi believes CZO has lost its major customer.
With Gilles saying CZO had $10 million cash in October and the ramping up of clinical trial costs for the avenanthramide pill, the costs associated with the merger, and the simultaneous ramping up on PGX to 50L and 100L plus the costs of the study with the Angiogenesis Foundation and potentially for the fibrosis toxicology study(Gilles said a 6 month study required) how much cash does fossi believe will be left if the merger is rejected next month? CZO also said it had designed an animal trial for the immune booster.